A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is sold under the brand name Mounjaro and affects feelings of hunger and fullness,

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will study the impact of a weight-loss drug on work and productivity.

Sir Keir Starmer and his health secretary have been lauding the potential of the new generation of weight-loss drugs. Given as regular injections, the treatments – Wegovy and Mounjaro – mimic a hormone that makes people less hungry.

The weight loss jab Mounjaro will soon be made available to nearly a quarter of a million NHS patients, according to proposals made by the National Institute for Health and Care Excellence (Nice). Previously,

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy.

Unemployed people living with obesity could be given new weight loss jabs to help them get back into work, the health secretary has said. Wes Streeting suggested the latest generation of medicines including Ozempic and Mounjaro could be "lifechanging" for individuals and would ease pressure on the NHS.

Health Secretary Wes Streeting has suggested that new weight loss injections such as Ozempic or Mounjaro could be given to the jobless to help them find work as 'widening waistbands' are putting press

The UK government starts a trial offering weight loss drug Mounjaro to unemployed obese individuals to improve health and workforce reentry. The initiative is part of a five-year NHS strategy. Eli Lilly commits £279 million to address Britain's health challenges,